$2.32
-0.015[-0.64%]
At close: Apr 19
$2.32
0[0.00%]
PreMarket: 4:13AM EDT
Adaptive Biotechnologies
(NASDAQ:ADPT)Adaptive Biotechnologies Stock (NASDAQ:ADPT), Analyst Ratings, Price Targets, Predictions
Adaptive Biotechnologies Corp has a consensus price target of $18.11, established from looking at the 24 latest analyst ratings. The last 3 analyst ratings were released from BTIG, Goldman Sachs, and JP Morgan on April 4, 2024, February 16, 2024, and February 15, 2024. With an average price target of $6 between BTIG, Goldman Sachs, and JP Morgan, there's an implied 158.62% upside for Adaptive Biotechnologies Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
BTIG
Goldman Sachs
JP Morgan
Piper Sandler
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Adaptive Biotechnologies
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/04/2024 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 115.52% | BTIG | Mark Massaro | $6 → $5 | Maintains | Buy | Get Alert |
| 02/16/2024 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 115.52% | Goldman Sachs | Salveen Richter | $11 → $5 | Maintains | Neutral | Get Alert |
| 02/15/2024 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 244.83% | JP Morgan | Rachel Vatnsdal | $11 → $8 | Maintains | Overweight | Get Alert |
| 11/13/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 158.62% | Piper Sandler | David Westenberg | $13 → $6 | Maintains | Overweight | Get Alert |
| 10/24/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 331.03% | Morgan Stanley | Tejas Savant | $13 → $10 | Maintains | Equal-Weight | Get Alert |
| 10/16/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 460.34% | Piper Sandler | David Westenberg | $14 → $13 | Maintains | Overweight | Get Alert |
| 08/08/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 503.45% | Piper Sandler | David Westenberg | $15 → $14 | Maintains | Overweight | Get Alert |
| 08/04/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 460.34% | Morgan Stanley | Tejas Savant | $14 → $13 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 503.45% | Morgan Stanley | Tejas Savant | $15 → $14 | Maintains | Equal-Weight | Get Alert |
| 02/16/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 546.55% | Morgan Stanley | Tejas Savant | $16 → $15 | Maintains | Equal-Weight | Get Alert |
| 02/15/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 201.72% | Credit Suisse | Dan Leonard | → $7 | Reiterates | → Underperform | Get Alert |
| 01/05/2023 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 546.55% | Scotiabank | Sung Ji Nam | → $15 | Initiates | → Sector Outperform | Get Alert |
| 12/21/2022 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 503.45% | Piper Sandler | David Westenberg | $7.5 → $14 | Upgrade | Neutral → Overweight | Get Alert |
| 11/07/2022 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 589.66% | Morgan Stanley | Tejas Savant | $17 → $16 | Maintains | Equal-Weight | Get Alert |
| 10/26/2022 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 223.28% | Piper Sandler | David Westenberg | $12 → $7.5 | Maintains | Neutral | Get Alert |
| 08/25/2022 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 244.83% | Credit Suisse | Dan Leonard | → $8 | Initiates | → Underperform | Get Alert |
| 08/17/2022 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 417.24% | Piper Sandler | David Westenberg | $7.5 → $12 | Maintains | Neutral | Get Alert |
| 06/03/2022 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 223.28% | Piper Sandler | David Westenberg | → $7.5 | Initiates | → Neutral | Get Alert |
| 05/24/2022 | ADPT | Buy Now | Adaptive Biotechnologies | $2.32 | 331.03% | Goldman Sachs | Salveen Richter | $14 → $10 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Adaptive Biotechnologies (ADPT)?
The latest price target for Adaptive Biotechnologies (NASDAQ: ADPT) was reported by BTIG on April 4, 2024. The analyst firm set a price target for $5.00 expecting ADPT to rise to within 12 months (a possible 115.52% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Adaptive Biotechnologies (ADPT)?
The latest analyst rating for Adaptive Biotechnologies (NASDAQ: ADPT) was provided by BTIG, and Adaptive Biotechnologies maintained their buy rating.
When was the last upgrade for Adaptive Biotechnologies (ADPT)?
The last upgrade for Adaptive Biotechnologies Corp happened on December 21, 2022 when Piper Sandler raised their price target to $14. Piper Sandler previously had a neutral for Adaptive Biotechnologies Corp.
When was the last downgrade for Adaptive Biotechnologies (ADPT)?
There is no last downgrade for Adaptive Biotechnologies.
When is the next analyst rating going to be posted or updated for Adaptive Biotechnologies (ADPT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Adaptive Biotechnologies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Adaptive Biotechnologies was filed on April 4, 2024 so you should expect the next rating to be made available sometime around April 4, 2025.
Is the Analyst Rating Adaptive Biotechnologies (ADPT) correct?
While ratings are subjective and will change, the latest Adaptive Biotechnologies (ADPT) rating was a maintained with a price target of $6.00 to $5.00. The current price Adaptive Biotechnologies (ADPT) is trading at is $2.32, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.